Cost-utility analysis of different treatments for post-traumatic stress disorder in sexually abused children by Gospodarevskaya, Elena & Segal, Leonie
	 	
	
 
 
This is the published version:  
 
Gospodarevskaya,	Elena	and	Segal,	Leonie	2012,	Cost‐utility	analysis	of	different	treatments	for	
post‐traumatic	stress	disorder	in	sexually	abused	children,	Child	&	adolescent	psychiatry	&	mental	
health,	vol.	6,	no.	15,	pp.	1‐15.	
	
	
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30064413	
	
	
	
Reproduced	with	the	kind	permission	of	the	copyright	owner	
	
	
Copyright	:	2012,	BioMed	Central	
RESEARCH Open Access
Cost-utility analysis of different treatments for
post-traumatic stress disorder in sexually abused
children
Elena Gospodarevskaya1* and Leonie Segal2
Abstract
Background: Post-traumatic stress disorder (PTSD) is diagnosed in 20% to 53% of sexually abused children and
adolescents. Living with PTSD is associated with a loss of health-related quality of life. Based on the best available
evidence, the NICE Guideline for PTSD in children and adolescents recommends cognitive behavioural therapy (TF-
CBT) over non-directive counselling as a more efficacious treatment.
Methods: A modelled economic evaluation conducted from the Australian mental health care system perspective
estimates incremental costs and Quality Adjusted Life Years (QALYs) of TF-CBT, TF-CBT combined with selective
serotonin reuptake inhibitor (SSRI), and non-directive counselling. The “no treatment” alternative is included as a
comparator. The first part of the model consists of a decision tree corresponding to 12 month follow-up outcomes
observed in clinical trials. The second part consists of a 30 year Markov model representing the slow process of
recovery in non-respondents and the untreated population yielding estimates of long-term quality-adjusted survival
and costs. Data from the 2007 Australian Mental Health Survey was used to populate the decision analytic model.
Results: In the base-case and sensitivity analyses, incremental cost-effectiveness ratios (ICERs) for all three active
treatment alternatives remained less than A$7,000 per QALY gained. The base-case results indicated that non-
directive counselling is dominated by TF-CBT and TF-CBT + SSRI, and that efficiency gain can be achieved by
allocating more resources toward these therapies. However, this result was sensitive to variation in the clinical
effectiveness parameters with non-directive counselling dominating TF-CBT and TF-CBT + SSRI under certain
assumptions. The base-case results also suggest that TF-CBT + SSRI is more cost-effective than TF-CBT.
Conclusion: Even after accounting for uncertainty in parameter estimates, the results of the modelled economic
evaluation demonstrated that all psychotherapy treatments for PTSD in sexually abused children have a favourable
ICER relative to no treatment. The results also highlighted the loss of quality of life in children who do not receive
any psychotherapy. Results of the base-case analysis suggest that TF-CBT + SSRI is more cost-effective than TF-CBT
alone, however, considering the uncertainty associated with prescribing SSRIs to children and adolescents,
clinicians and parents may exercise some caution in choosing this treatment alternative.
Background
It is estimated that 5-10% of girls and 1-5% of boys in high
income countries are exposed to penetrative sexual abuse
during childhood, with even higher prevalence rates if any
form of sexual abuse is included [1]. Although between
1/2 and 2/3 of sexually abused symptomatic children
improve over time [2], mental health consequences can be
debilitating and the process of recovery may take many
years and even result in premature mortality [3]. Post-
traumatic stress disorder (PTSD) is frequently observed in
sexually abused children who are often diagnosed with
other mental health co-morbidities (e.g. anxiety, depres-
sion). PTSD and co-morbid depression are associated with
an increased risk of suicide [4]. Studies conducted in the
US population of sexually abused children reported the
prevalence of PTSD ranging between 20% and 53% [2,5-7].
PTSD is characterised by symptoms lasting more than
one month following an extremely traumatic event
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which the person experienced or witnessed (e.g. combat,
terrorist attack or natural disaster). PTSD was first
introduced in the Diagnostic and Statistical Manual of
Mental Health Disorders in 1980 [8]. In 2000, childhood
sexual abuse was recognised as a qualifying traumatic
event [9], which typically results in intense fear, help-
lessness or horror. Three clusters of symptoms are asso-
ciated with PTSD: re-experiencing the traumatic event,
avoidance or emotional numbing and hyper-arousal.
Re-experiencing may present in one or more of the fol-
lowing ways: intrusive recollections; recurring night-
mares; acting or feeling as if the event were recurring;
distress when reminded of the event; or physiological
reactivity when reminded of the event. Children may
also re-experience the traumatic event in the form of
trauma-thematic spontaneous play. Symptoms of avoid-
ance involve efforts to avoid thoughts, feelings, activities,
places or people that arouse recollections of the event,
inability to recall aspects of the trauma, and diminished
interest or participation in significant events. In chil-
dren, avoidance may lead to a restricted lifestyle, refusal
to separate from parents and difficulty experiencing ten-
der or loving feelings. Adolescents may resort to drug
and alcohol abuse and demonstrate a foreshortened
view of the future, being unable to envisage growing to
maturity and having a long and fulfilling life. Symptoms
of increased arousal involve difficulty falling or staying
asleep; irritability or outbursts of anger; difficulty con-
centrating; hyper-vigilance (e.g. excessive checking of locks
in the home and over-concern about health and welfare of
parents); or an exaggerated startle response [10]. To be
diagnosed with PTSD, children must exhibit at least one
re-experiencing symptom, three avoidance/numbing
symptoms, and two increased arousal symptoms [9].
The high prevalence of PTSD associated with sexual
abuse led to the development of specialist psychothera-
peutic treatments for which a reduction of PTSD symp-
toms is the primary outcome. In 2005, the UK National
Institute for Health and Clinical Excellence (NICE) com-
missioned the National Collaborating Centre for Mental
Health to produce a Clinical Practice Guideline for Man-
agement of PTSD in Adults and Children. Development
of this PTSD Guideline included a systematic assessment
of eight randomised controlled trials (RCTs) involving
children with substantiated contact sexual abuse [11-19].
On the basis of available evidence the PTSD Guideline
recommended 8-12 individual weekly Trauma-Focused
Cognitive Behavioural Therapy (TF-CBT) sessions with
the child over non-directive supportive counselling or
standard community treatment for treating PTSD in chil-
dren and adolescents [20]. There was insufficient evi-
dence to support recommendation of other types of
treatment such as play therapy or art therapy [20].
TF-CBT is a flexible component-based manualised treat-
ment that typically includes relaxation skills, affective reg-
ulation skills, cognitive coping skills, trauma narrative and
cognitive processing of the traumatic events, psychoeduca-
tion and parenting skills [21]. The core principle of TF-
CBT is the “gradual exposure” of the child to the child’s
traumatic experience, where the intensity of the exposure
incrementally and systematically increases throughout the
treatment process. Non-directive supportive counselling
typically includes establishing a trusting therapeutic rela-
tionship by providing active listening, reflection, accurate
empathy, encouragement to talk about feelings and belief
in the child’s and parent’s ability to develop positive
coping strategies for abuse-related difficulties. Unlike
TF-CBT, non-directive counselling is not a manualised
treatment. It is primarily non-advisory but may include
some elements of psycho-education about stress reaction
and normalisation of PTSD symptoms [20].
In addition to recommendations regarding the content
of therapy, the PTSD Guideline reviewed evidence and
provided guidance regarding the modality of treatment.
Although parental participation was not associated with
additional PTSD-related clinical benefit for a child in the
short term [16], the Guideline acknowledged the impor-
tance of parental reactions to the successful treatment of
PTSD. Participating in treatment may reduce the level of
anxiety in parents and carers and also improves their con-
fidence and parenting practices, which may benefit the
child over the long term [22]. However, the Guideline
advised against treatment modalities involving only
parents.
Depression is the most commonly observed co-morbid-
ity in persons diagnosed with PTSD [23] and the associa-
tion between these conditions was extensively researched
(see Methods section below). The NICE guideline for
treatment of depression in children and young people was
consistent with the PTSD Guideline in its recommenda-
tion of CBT and supportive non-directive therapy as the
treatment of first choice for depression in children and
adolescents [24]. However, the Depression Guideline dif-
fers from the PTSD Guideline in relation to the use of
pharmacotherapy in treatment of mental health conditions
in children and adolescents. The Depression Guideline
endorsed the use of fluoxetine in treatment of moderate to
severe depression and the broader range of selective sero-
tonin reuptake inhibitors (SSRIs) such as sertraline, citalo-
pram, and paroxetine for depression unresponsive to
psychotherapy. Pharmacotherapy is to be provided along
with psychological therapy and the patients are to be mon-
itored carefully for the appearance of suicidal behaviour.
In contrast, the PTSD Guideline rejected the practice of
“off-label” prescribing of psychotropic drugs for children
[25-27], citing evidence of increased suicidal ideations and
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behaviour in young people who were taking SSRIs [28-30].
Currently, no SSRIs are approved for the treatment of
PTSD in the USA paediatric population, however numer-
ous authors have addressed the question of whether it is
safe to use SSRIs in children. For example, a meta-analysis
of 15 antidepressant trials [31] found no statistically signif-
icant difference in suicidal thoughts and behaviours
between patients receiving antidepressants and those
receiving placebo for depression. The authors concluded
that the benefits of antidepressants appear to be much
greater than risks from suicidal ideation and behaviour in
depressed children and adolescents [31,32]. In relation to
the study population of children and adolescents with
PTSD secondary to sexual abuse, the apparent benefit of
adding SSRI to psychotherapy was demonstrated in a
small-size double-blind RCT in 10- to 17-year olds. The
study compared outcomes of the intervention group
assigned to 12 weekly individual TF-CBT sessions and
SSRI (sertraline) with outcomes of the control group
assigned to TF-CBT and placebo [33]. The number of
children no longer meeting the full PTSD criteria (treat-
ment responders) was higher in the TF-CBT and sertraline
group, although the trial was underpowered to detect a
statistically significant difference. All children with co-
morbid depression (58% in each group) were among the
treatment responders. The two groups showed no signifi-
cant difference in measures of suicidal ideation at any
observation point during the study.
To summarise, it appears that there is clinical evi-
dence supporting the following treatments available to
sexually abused children and adolescents who met all or
most of diagnostic criteria for PTSD.
• Individual TF-CBT sessions with the child alone.
This manualised treatment involves 12 sessions of 45
minutes duration provided on a weekly basis [12-16,18].
There is some limited evidence that a variation of TF-
CBT, called Eye Movement Desensitization and Repro-
cessing treatment, which is also based on the concept of
gradual exposure of sexually abused children to their
traumatic experience is equally effective in treatment of
PTSD as the standard TF-CBT [17].
• A combination therapy involving 12 individual paral-
lel 45 min TF-CBT sessions with the child and non-abu-
sive parent and SSRI [33].
• Twelve individual non-directive supportive counsel-
ling sessions of 45 min duration (used as a control
group in some RCTs [12-15]).
CBT and individual non-directive supportive counsel-
ling are recommended as the first line treatment of
depression in children and adolescents [24]; for severe
depression a combination of psychiatric treatment and
SSRIs can be considered. SSRIs (and sertraline in parti-
cular) are recommended as the second line treatment
for those who do not respond to TF-CBT or non-direc-
tive counselling.
Although there was no experimental study that
included all three of the recommended treatment alterna-
tives (TF-CBT, TF-CBT + SSRI, and non-directive sup-
portive counselling) in a single RCT, their comparative
effectiveness in terms of the proportion of treatment
responders (i.e. children who no longer meet the PTSD
diagnostic criteria at the end of treatment) can be
assessed using the method of indirect comparisons [34].
Allocating limited health care resources to the most cost-
effective PTSD treatments would affect the balance of
health benefits and costs for society; however there is a
paucity of evidence regarding the cost-effectiveness of
treatments in child and adolescent mental health [35].
Economic evaluation can assist by comparing costs and
outcomes of different treatments and identifying those
treatments with the lowest cost per unit of health gain
[36]. Shifting resources away from services that are high
cost per unit of health gain to those with a low cost per
unit of health gain would increase the total health and
wellbeing of society.
This paper employs a method of modelled economic
evaluation to undertake a cost-utility analysis of differ-
ent treatments for PTSD (individual TF-CBT with child;
a combined treatment involving TF-CBT with child and
pharmacotherapy (SSRI), and non-directive supportive
counselling) versus a “no treatment” comparator. The
“no treatment” comparator is routinely used in modelled
economic evaluations, however in this particular analysis
it acquires a real practical interpretation because not all
sexually abused children with mental health problems
are identified and subsequently treated. Cost-utility ana-
lysis produces incremental cost effectiveness ratios
(ICER) comparing costs and outcomes of each of these
treatments against a “no treatment” comparator and
each other. The outcomes are expressed in quality-
adjusted life years (QALYs), the measure of health that
combines the effects of disease upon morbidity (e.g. the
presence of PTSD and/or depression) and mortality (e.g.
suicides in adolescents with a history of sexual abuse).
The base-case analysis is conducted from the perspec-
tive of the Australian mental health system and does
not assume any particular distribution of children across
the treatment alternatives.
Methods
Outline of the economic model
The modelled economic evaluation of different treat-
ments for sexually abused children with PTSD consists of
two parts. The first part is a decision tree that models the
costs and effects corresponding to the post-treatment
and 12 month follow-up outcomes reported in RCTs of
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clinical interventions (TF-CBT, TF-CBT in combination
with SSRI, and non-directive supportive counselling) and
a no treatment comparator [15,16,33]. In these trials clin-
ical effectiveness was reported in terms of proportions of
treatment responders (i.e. children who no longer met
DSM-IV diagnostic criteria for PTSD). The clinical effec-
tiveness estimates were used to determine what propor-
tions of the baseline cohort is assigned to “PTSD”,
“PTSD + depression” or “no PTSD/no Depression” health
states at the end of 12 months. The second part of the
model is a Markov process that calculates the long-term
costs and outcomes in sexually abused children with
PTSD or PTSD and depression over the next 30 year
time interval.
The purpose of the decision tree is to model the treat-
ment effect observed in the RCTs that inform the eco-
nomic evaluation [15,16,33]. For each of the three active
treatments and the no treatment alternative, the deci-
sion-tree tracks the proportion of the model cohort
reaching the following health states at the end of 12
months: a) remission from PTSD (and depression if pre-
sent at the baseline), and b) still meeting full diagnostic
criteria for PTSD (and depression if present at the
baseline).
A schematic representation of the base-case model
structure for the decision tree is shown in Figure 1. The
model differentiates between responders and the small
proportion of apparent non-responders who may experi-
ence a delayed treatment response [16,18]. For delayed
responders, treatment response was assumed to occur 3
months after completion of 12 sessions (i.e. at mid-
point of the 12 month time interval modelled with the
decision tree). Delayed responders were assigned health
benefits for 6 out of 12 months, while those who were
no longer meeting PTSD diagnostic criteria at the post-
treatment assessment were assigned health benefits for 9
out of 12 months. The rest of the treatment non-
responders who at the baseline were diagnosed with
PTSD or PTSD and depression were assumed to remain
in these respective health states at the end of the 12
month time interval.
The objective of the Markov model is to estimate the
long-term health and cost consequences for the model
cohort over the next 30 years (i.e. the surviving propor-
tion of cohort would be 41 years old at the end of the last
Markov cycle). The model time horizon includes the age
interval corresponding to the increase in the rates of sui-
cide, which occurs between 20 to 34 years of age in males
Figure 1 Structure of the decision tree part of the modelled economic evaluation with 12 month time horizon. PTSD - Post traumatic
stress disorder; TF-CBT - Trauma-Focused Cognitive Behavioural Therapy; SSRI - Selective Serotonin Reuptake Inhibitor.
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and between 24 to 29 years of age in females [37] and
captures all health benefits associated with PTSD treat-
ment and gradual spontaneous recovery from PTSD
which is observed in about 2/3 of the baseline cohort by
the age of 40. Consistent with the USA epidemiological
evidence, the remaining part of the cohort (34%) is
assumed not to recover from the PTSD associated with
childhood sexual abuse [38].
Health benefits are measured in QALYs, which are
defined as the product of life years and a preference-
based index of quality of life (utility weight). Utility
weights reflect subjective valuations of the relative worth
of different health states where “1” represents perfect
health and “0” represents death. Health states perceived
as worse than death are allowed and carry a negative
value. Utility weights exhibit equal interval properties
and an equivalence with life years (e.g. a reduction of 0.2
quality of life utility score over 5 years is equivalent to
the loss of 1 life year). Utility weights can be directly
obtained from patients or the general public using mea-
surement techniques such as the time trade-off or stan-
dard gamble [36]. Alternatively, off-the-shelf weights
from questionnaires such as the Assessment of Quality of
Life - AQoL [39] or European Quality of Life five dimen-
sions - EQ-5D [40] can be applied to the population of
interest. Total QALYs are then estimated by aggregating
the utility-adjusted time intervals that patients spent in
each subsequent health state. In estimating long-term
costs and health consequences, it is assumed that the dif-
ference in effectiveness between the treatments only
relates to the first 12 months for which the post-treat-
ment and follow-up effectiveness outcomes are available.
Subsequently the probabilities and payoffs (i.e. costs and
utilities) of recurrent mental health problems (e.g.
depression observed after the 12 month interval or the
ongoing spontaneous recovery from PTSD experienced
by a proportion of the cohort over the next 30 years) are
independent from the evaluated treatments. Estimates of
the expected long-term survival and costs are therefore
conditional only on each patient’s health state at the end
of the 12 months.
In the Markov part of the model the cohort moves
through mutually exclusive health states representing the
possible mental health consequences associated with an
experience of childhood sexual abuse. The model
includes pathways for the gradual recovery from PTSD in
those who did not respond to treatment and for recur-
rent-remitting depression (see below for further clarifica-
tion). These are reflected as a set of possible transitions
between the health states over a series of discrete time
periods (cycles). The duration of the cycle in the model is
3 months with patients assumed to transition between
states half-way through each cycle. Children and young
adults who spend 3 months in any particular health state
are assigned a utility value associated with this health
state and may attract the cost of SSRI, if experiencing an
episode of depression. The expected value of costs and
QALYs are then calculated by adding the costs and
health benefits across the states and weighting according
to the time the person is expected to stay in each health
state [41]. The structure of the Markov part of the model
is shown in Figure 2.
Pathways included in the economic model
The Markov model characterises disease process in terms
of nine states (depicted as circles) and arrows indicating
the transitions patients can make in the model. Respon-
ders to PTSD treatment start the progression through
Markov cycles at the state of no PTSD/no depression.
Non-responders start either at the PTSD only state or
PTSD + depression if depression was present at the base-
line. There are complex dynamics between PTSD and
depression such that pre-existing depression increases
susceptibility to developing PTSD in response to the
traumatic event, while PTSD increases the risk for the
first onset of depression [4].
However this Markov model, as all modelled economic
evaluations, presents a simplified version of all possible
variations of the lifetime history of PTSD with or without
co-morbid depression. Because the objective is to evaluate
treatments for PTSD secondary to childhood sexual abuse,
any re-occurrence of PTSD due to subsequent traumatic
life events is outside the scope of the evaluation. That
implies that once PTSD is successfully treated there
assumed to be no relapse associated with the original trau-
matic experience of sexual abuse. This is depicted in
Death from suicide 
due to depression 
Death from 
suicide due to 
PTSD 
Death from suicide 
in general 
population 
PTSD + 
depression 
Death from 
suicide due 
PTSD+depression 
Death from 
other causes 
No 
PTSD/no 
depression 
PTSD only 
 
Depression 
only 
Figure 2 Patient flow diagram for Markov model.
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Figure 2 by a one-way arrow connecting the health state
“PTSD only” with the health state “No PTSD/no
depression”.
While relapse to PTSD is not permitted in the model,
the depression pathway is modelled differently; allowing
for the recurrent-remitting nature of this mental health
condition [42,43]. In Figure 2 the re-occurrence of depres-
sion in some children who responded to PTSD treatment
and the subsequent recovery is depicted with a two-way
arrow connecting the “No PTSD/no depression” state with
the “Depression only” state. Children who at the baseline
were diagnosed with both PTSD and depression but did
not respond to treatment at the end of 12 months were
subsequently administered SSRI as a second line treatment
for depression as recommended by the clinical Guideline
and existing practice [24,44]. The probability of success-
fully recovering from depression (obtained from the recent
large RCTs) was applied to the proportion of patients who
are compliant with the SSRI regimen [45]. This proportion
of the cohort will progress to the “PTSD only” state. The
model also assumes that a proportion of untreated chil-
dren may experience a spontaneous recovery from depres-
sion, including those who may withdraw from the
treatment because of side-effects. Those who responded to
SSRI treatment for depression were assumed to continue
on medication under supervision for the next 9 months
after discontinuation of depression symptoms. This
assumption is in line with evidence suggesting that longer
medication continuation periods, possibly for one year,
may be necessary for relapse prevention [46].
It should be noted that, consistent with the existing evi-
dence, transition from the “PTSD + depression” state to
“Depression only” is not allowed in the population of
sexually abused children who are eligible for PTSD treat-
ment (the baseline cohort). Firstly, it was demonstrated
that the high rate of co-morbid depression in patients
with PTSD is related to the same personal vulnerabilities.
In other words, the hypothesis that traumatic life events
increase the risk of depression independently of their
PTSD effects was refuted [47]. Secondly, the existing evi-
dence suggests that successful treatment of PTSD also
results in remission of co-morbid depression with a 100%
response rate in eligible patients [33,48]. However, elig-
ibility for PTSD treatment may be compromised in
patients with a co-morbid depression so severe that it
makes PTSD treatment based on “exposure” methods
impossible [20]. In such instances depression should be
treated ahead of PTSD treatment. In either case, the posi-
tive treatment outcome that is limited to PTSD and not
associated with greatly reduced symptoms of depression
is unlikely.
The current evidence suggests that in comparison to
the rates of suicides in the general population, children
and adolescents suffering from PTSD or depression and
especially from PTSD associated with co-morbid depres-
sion demonstrate higher rates of suicides [4,49-52]. The
model includes age-related probabilities of suicide for
each of the following health states: the PTSD + depres-
sion, PTSD only and Depression only to capture the
long-term consequences of mental health interventions
in terms of reduced rates of suicide.
According to the epidemiological evidence obtained for
the purpose of this modelled economic evaluation, a pro-
portion of children who did not respond to treatment for
PTSD will eventually recover, although the process of
recovery may take between two to 30 years. These esti-
mates were obtained by the authors from an analysis of
the 2007 Australian National Survey of Mental Health
and Wellbeing data on duration of a PTSD episode
believed to be associated with childhood sexual abuse
[53]. Time-related transition probabilities from “PTSD
only” to “No PTSD/no depression” were included in the
model to reflect these respondents’ (N = 124) time to
recovery from PTSD onset. It was observed that in about
one third of patients PTSD will persist for the rest of
their lives. This is consistent with the estimated propor-
tion of non-remitting PTSD patients observed in the
USA population [38].
Characteristics of the population included in the model
The demographic and clinical characteristics of the chil-
dren included in the model cohort reflected the selection
criteria of the RCTs that provided the estimates of clinical
effectiveness for each of the evaluated interventions
[15,16,33]. The baseline cohort consisted of 10-year-old
children who met either all or most of the PTSD diagnos-
tic criteria, including at least one symptom of avoidance or
re-experiencing. Because PTSD often presents with
delayed onset, the exclusion of children who did not meet
full PTSD criteria at baseline was unwarranted [16]. For
the purposes of economic evaluation the clinical outcomes
were expressed in terms of the response rate (i.e. the pro-
portion of children who were “PTSD-positive” at the base-
line and “PTSD-negative” at post-treatment and the
follow- up). Consequently, the children who did not meet
the full PTSD diagnostic criteria at the baseline could not
be considered responders at the post-treatment assess-
ment either, although their trauma-related symptoms
were improved [16]. The conservative definition of the
“response rate” employed here resulted in an underesti-
mate of clinical effectiveness of treatments and subse-
quently a conservative estimate of incremental cost-
effectiveness ratios against the “no treatment” comparator.
Children with psychiatric conditions that may be contrain-
dicated to TF-CBT (e.g. severe developmental delay, psy-
chosis, suicidal and dangerous or aggressive behaviour)
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were excluded. It was also required that any contact with
an identified person involved in child sexual abuse had
been discontinued.
Data used in the model
The 2007 Australian National Survey of Mental Health
and Wellbeing collected data from 8,841 participants aged
16 to 85 [53]. The survey included a generic preference-
based instrument AQoL-4D for assessing health-related
quality of life [39]. This particular version of AQoL used
12 scales to measure the interference that health problems
in the week prior to the interview had on personal care,
household tasks, ability to move around the house and
community, personal relationships, relationships with
other people; relationships with family, vision, hearing,
communication with others, sleeping habits, feelings in
general, and level of pain or discomfort. The responses to
the AQoL-4D questionnaire by children and adolescents
with a history of childhood sexual abuse who also met the
DSM-IV diagnostic criteria for PTSD, PTSD + depression,
or only depression were used to calculate utility estimates
[54]. Utility values of 0.61 (SE = 0.08), 0.53 (SE = 0.09) and
0.46 (SE = 0.09) were used for the health states “PTSD
only”, “PTSD + depression” and “depression only” respec-
tively for the entire time interval included in the modelled
economic evaluation. The utility value of 0.87 observed in
the 16-21 year old population without a history of sexual
abuse was identical to the published AQoL-4D utility
observed in the general population. This value was applied
to the proportion of the cohort who either responded to
treatment or experienced a spontaneous recovery over the
age interval of 10-30. A slightly smaller value of 0.85 was
used for the proportion of the cohort who remained in the
“no PTSD/no depression” state when they were 30 to 40
years old [54].
Age-specific transition probabilities for the state “Death
from other causes” were obtained from the Australian
2007-2009 Life Tables [52] and adjusted for the propor-
tion of age-specific deaths from suicides in general popu-
lation [37]. Suicide rates associated with other mental
health conditions (Markov states “PTSD + depression”,
“PTSD only” and “Depression only”) were obtained from
the published literature [4,49-51].
Categories of mental health system resource use were
obtained from the identified RCTs that provided clinical
effectiveness estimates for the economic evaluation
[15,16,33]. Resource use included the cost of therapists’
time in providing 12 individual 45 minute TF-CBT or
non-directive individual psychotherapy sessions per
child in each of the active treatment arms. The cost of
SSRI therapy (sertraline) was added to TF-CBT + SSRI
treatment arm. Since psychotherapy can be provided by
either psychologists or psychiatrists, it was assumed that
each category of these mental health professionals
treated one half of the cohort. The unit costs (scheduled
fees) for psychologists and psychiatrists were taken from
the MBS [55] and assumed to cover patient contact
time, patient-related indirect time and overheads in pub-
licly-funded youth mental health facilities. The cost of
sertraline was taken from the Schedule of Pharmaceuti-
cal Benefits [56]. Since the PTSD Guideline are not spe-
cific about the form of non-abusive parent involvement
in treatment, for the purpose of this study it was conser-
vatively assumed that each parent received either one
individual psychoeducational session with a social
worker or participated in six parental group sessions.
Cost implications are the same regardless of the modal-
ity of the parental involvement. Table 1 shows the
model input parameters and the sources of the unit
costs.
Results of the modelled economic evaluation are pre-
sented in terms of incremental cost per QALY gained.
Results are presented separately for the 12 month time
interval that corresponds to the follow-up outcomes
reported in RCTs and for the long-term outcomes with
a time horizon of 31 years. The economic evaluation is
conducted from the perspective of the Australian mental
health care system; costs and benefits are expressed in
2010/2011 Australian dollars and discounted at a rate of
5% per year.
Uncertainty
All model parameters other than unit costs and popula-
tion utility norms were subjected to deterministic and
probabilistic sensitivity analyses. For some parameter
estimates (e.g. probabilities of spontaneous remission,
reoccurrence of depression and suicide rates) no mea-
sure of variability was available from the epidemiological
evidence. In the sensitivity analyses an arbitrarily chosen
30% variation range around each of the parameter point
estimates was used (i.e. the modelled results were recal-
culated for 70% and then for 130% of each point esti-
mate as shown in Table 1). Two-way sensitivity analysis
for TF-CBT and TF-CBT + SSRI clinical effectiveness
parameters was undertaken (i.e. the lower and upper
values were assigned to both treatment alternatives) to
account for the possible covariance between these two
treatment options because it was reasonable to assume
that effectiveness of TF-CBT is a component of effec-
tiveness of TF-CBT + SSRI. Utility estimates were
obtained by the first author from the Australian 2007
Mental Health Survey [53], which allowed testing the
robustness of the outcomes to variation in these model
parameters using firstly, the 30% sensitivity range and
secondly, the 95% confidence intervals. The small sam-
ple of the population available for calculating utility
values in sexually abused children who developed
adverse mental health consequences resulted in the
Gospodarevskaya and Segal Child and Adolescent Psychiatry and Mental Health 2012, 6:15
http://www.capmh.com/content/6/1/15
Page 7 of 15
Table 1 Parameter values used in the model
Parameter Value (range used in the
deterministic sensitivity
analysis)
Parameters used in
probabilistic
sensitivity analysis
Source
Clinical effectiveness for treating PTSD (and depression if present). Used in the
decision tree part of the model
Beta distribution
a b
TF-CBT only 0.42 (0.29 - 0.55)* 24.3 33.6 [15,16,33]**
TF-CBT + SSRI (setraline) 0.44 (0.31 - 0.57)* 23.5 29.9
Non-directive counselling 0.34 (0.24 - 0.44)* 27.8 54.0
Clinical effectiveness for treating recurrent depression (used in Markov part of the
model) with SSRI
SSRI only (applied to treatment non-responders, and responders who relapsed
into depression in the Markov part of the model)
0.6 (0.42 - 0.78) 16.5 11.0 [45,57]
Disease pathways parameters Beta distribution
a b
Proportion of the cohort with co-morbid depression 0.58 (0.40 - 0.75) [33]
Probability of delayed response to PTSD treatment (assumed to occur in the 6th
month after treatment)
0.17 (0.12 - 0.22) 35.3 172.1 [53]
Probability of spontaneous remission from PTSD (applied to the non- treated
population in the first 12 months)
0.17 (0.12 - 0.22) 35.3 172.1 [18,53]
Probability of spontaneous recovery from PTSD over 29 years (applied to the
treatment non-responders in Markov part of the model)
2 d year 0.0083 [53]***
3-4th years 0.0041
5-6th years 0.0021
7-8th year 0.0043
9-11th year 0.0035
12-13th years 0.0023
14-16th years 0.0013
17-20th years 0.0028
21-29 years 0.0020
Probability of spontaneous remission from depression 0.53 (0.37 - 0.69) 19.5 17.3 [45]
Probability of re-occurrence of depression in PTSD treatment responders 0.14 (0.09 - 0.18) 36.6 224.6 [33]
Mortality 0.0 (in 10-14 y.o.) [37,58]
Age-adjusted probability of suicide in general population (per 3-month cycle) 0.0000155 (in 15-19 y.o.)
0.0000316 (in 20-29 y.o.)
0.0000387 (in 30-40 y.o)
Age-adjusted probability of suicide in adolescents and young adults with PTSD +
depression (per 3-month cycle)
0.0 (in 10-14 y.o.) [37,49,58]
0.000334 (in 15-19 y.o.)
0.000343 (in 20-29 y.o.)
0.000744 (in 30-40 y.o)
Age-adjusted probability of suicide in adolescents and young adults with
depression only (per 3-month cycle)
0.0 (in 10-14 y.o.) [50]
0.000186 (in 15-19 y.o.)
0.000379 (in 20-29 y.o.)
0.000465 (in 30-40 y.o)
Age-adjusted probability of suicide in adolescents and young adults with PTSD
only (per 3-month cycle)
0.0 (in 10-14 y.o.) [51]
0.000032 (in 15-19 y.o.)
0.000066(in 20-29 y.o.)
0.000080 (in 30-40 y.o)
Age-adjusted probability of death from other causes except suicide in
adolescents and young adults (per 3-month cycle)
0.000027 (in 10-14 y.o.) [37,58]
0.000070 (in 15-19 y.o.)
0.000104(in 20-29 y.o.)
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counter-intuitive point estimates where utility associated
with depression only (0.46; N = 11) was less than utility
associated with PTSD + depression (0.53; N = 9),
although the difference was not statistically significant
indicating that variation in the estimates is likely due to
the randomness of the data. To investigate the effect of
variation in utility estimates we conducted a two-way
sensitivity analysis using the higher (0.53) and the lower
(0.46) point estimates for both utility values.
In addition, a probabilistic sensitivity analysis was con-
ducted. Firstly, the parameter estimates other than
population-based utility norms and suicide rates were
assigned a probability distribution as shown in Table 1.
Secondly, Monte-Carlo simulation was used to reflect
the uncertainty in the model’s results and calculate 95%
CI around estimates of costs and QALYs [41].
Results
Table 2 shows results of cost-effectiveness analysis with
a time horizon of 12 months (the decision tree part of
the model). Using the no-treatment option as a com-
parator, the observed difference in clinical effectiveness
translated into an incremental QALY gain ranging from
0.06 in non-directive supportive counselling to 1.0 in
TF-CBT + SSRI. The estimated ICERs of active treat-
ment vs. no treatment range from A$22,263 for TF-
Table 1 Parameter values used in the model (Continued)
0.000169 (in 30-40 y.o)
Mental health care resource use parameters Gamma distribution
a l
One month prescription of sertraline, (100 mg) $24.66 96.04 3.89 [56]
Cost per consultation with clinical psychologist/counsellor (MBS Australia Items
80000; 80010)
First consultation $140.90 96.04 0.68 [55]
Subsequent consultation
$96.00
96.04 1.00
Cost per consultation with clinical psychiatrist (MBS Australia Items 296; 304) First consultation $250.45 96.04 0.38 [55]
Subsequent consultation
$125.80
96.04 0.76
Cost per consultation with general practitioner (monitoring and SSRI renewal if
required)
$66.00 96.04 1.46 [59]
Cost of individual consultation with social worker or participation in 6 parental
group sessions (Social workers schedule fee, Items SW01; SW15).
$58.85 96.04 1.63 [60]
Utility values
Gamma distribution
No PTSD/No depression (population norm) a l
10-30 year olds 0.87
30-40 year olds 0.85 [53,54]
PTSD only 0.61 (0.43 - 0.79)*** 96.04 157.4
PTSD + depression 0.53 (0.37 - 0.69)*** 96.044 181.21
Depression only 0.46 (0.32 - 0.60)*** 96.044 208.78
*The aggregated sample size used in direct and indirect comparison of effectiveness of active treatments vs no treatment comparator was: N = 50 in TF-CBT [16];
N = 36 in TF-CBT + sertraline [16,33]; N = 116 in non-directive counselling [15,16]
**Clinical effectiveness (proportion of responders at the end of treatment) was adjusted for indirect comparison;
***Estimate obtained by the first author. (E. Gospodarevskaya “Prevalence of post-traumatic stress disorder, symptom duration and quality of life in sexually
abused Australian children: using mental health survey data for economic analysis"; Journal of Child Sexual Abuse, 2012. Forthcoming)
Table 2 Results of the 12 month decision tree analysis
Treatment
options
Total cost per
child (A$2010-
2011)
Total
QALYs
Incremental QALYs
vs no treatment
Incremental cost per QALY
gained vs no treatment
Incremental cost per QALY gained
(comparing to non-dominated
treatments)
No treatment 0 0.87 - - -
Non-directive
counselling
2074.0 0.93 0.06 34,567 Dominated by TF-CBT
TF-CBT only 2051.1 0.96 0.09 22,790 (2226.3-2051.1)/(0.97-0.96) = 17,520
TF-CBT + SSRI
(sertraline)
2226.3 0.97 0.10 22,263
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CBT + SSRI to A$34,567 for non-directive counselling,
indicating that even in the short term investing in any
type of psychotherapy is likely to present a good value
for money from the perspective of the Australian mental
health system if the threshold of A$50,000 per QALY
gained is considered ‘affordable’ [61].
The Markov model with a 30-year time horizon was
designed to trace down the long-term costs associated
with recurrent-remittent depression and the benefits
associated with an improved quality of life and reduced
rates of suicides in treatment responders. As explained
in the Methods section, the model is limited to its
objective of evaluating alternative therapies for treat-
ment of PTSD secondary to childhood sexual abuse.
Consistent with its objective, any costs associated with
any subsequent PTSD related to other traumatic events
are not included in the model. The prognostic model
effectively translates benefits of treatment (QALYs
gained) accrued during the initial 12 month interval into
differences in long-term costs and QALYs. In the long-
term cost-effectiveness analysis the discounted benefit of
QALY gains associated with a reduction in suicide rates
that would otherwise increase in 10 to 20 years after
PTSD treatment was smaller than the accumulated
effect associated with the QALY gain obtained by the
treatment responders at 12 months. Table 3 shows the
results of the base-case analysis of the long-term Mar-
kov model. The estimated ICERs of active treatments vs.
no treatment range from just over A$1,650 for TF-CBT
only to under A$2,100 for non-directive counselling.
The Guideline for Management of PTSD in Adults
and Children [20] recommended TF-CBT over the non-
directive counselling. Consistent with this recommenda-
tion, results of both the short- and long-term modelled
economic evaluation indicated that TF-CBT generated
more QALYs and cost less than non-directive suppor-
tive counselling (i.e. dominating this treatment option).
The combination therapy of TF-CBT and SSRI gener-
ated more QALYs than either non-directive counselling
or TF-CBT only options. However, quite predictably,
the combination therapy was more expensive than TF-
CBT alone in either the short- or long-term versions of
the model.
Extensive one-way sensitivity analyses were conducted
by varying the model parameters as indicated in Table 1.
The primary objective of the analysis was to identify the
parameter values associated with the ICER exceeding the
A$50,000 threshold. The secondary objective of the sen-
sitivity analysis was to determine the parameter values
that change the order of preference in the active treat-
ments established in the base-case analysis.
Results were robust with respect to variation in most
parameters of the model (e.g. rates of suicides, probability
of spontaneous remission from PTSD, proportion of
cohort with co-morbid depression, probability of delayed
response to PTSD treatment, effectiveness of SSRI for
treatment of depression and health state specific utility
estimates). The results of these sensitivity analyses showed
that non-directive supportive counselling remained more
costly and less effective than the TF-CBT treatment. The
TF-CBT + SSRI treatment remained the most effective
but also the most expensive of the active treatment alter-
natives. In each case the ICERs for these preferred treat-
ment options remained below A$2,000 using a no
treatment alternative as a comparator. The only exception
was ICER estimates for the upper limit of the utility esti-
mate for PTSD (0.79). The ICER values were A$6,513 for
TF-CBT and A$6,617 for TF-CBT + SSRI, with non-direc-
tive counselling dominated by these treatment options.
When the sensitivity analysis was replicated using the 95%
CI for utility estimates, the results changed very little
because the 30% parameter variation range was slightly
larger than the 95% CI. Conducting a two-way sensitivity
analysis with both utility values for PTSD + depression
and depression only assigned firstly the value of 0.53 and
then the value of 0.46, produced only a small variation in
the results of the base-case analysis and did not affect the
overall conclusions.
At the upper limit of the probability of successful PTSD
treatment with non-directive counselling (0.44), this treat-
ment option dominated both TF-CBT and TF-CBT +
SSRI treatment options. Under these assumptions TF-
CBT and TF-CBT + SSRI generated about the same num-
ber of QALYs but were marginally more expensive than
non-directive counselling with the ICERs of A$1,650 and
A$1,706 respectively. When the clinical effectiveness of
Table 3 Results of the base-case analysis of the model with the 31 year time horizon
Treatment
options
Total cost per
child (A$2010-
2011)
Total
QALYs
Incremental QALYs
vs no treatment
Incremental cost per QALY
gained vs no treatment
Incremental cost per QALY gained
(comparing to non-dominated
treatments)
No treatment 0 11.59 - - -
Non-directive
counselling
2123.2 12.61 1.02 2081.57 Dominated by
TF-CBT only 2095.7 12.86 1.28 1650.16 (2269.8-2095.7)/(12.92-12.86) = 2901.7
TF-CBT + SSRI
(sertraline)
2269.8 12.92 1.34 1706.61
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both TF-CBT and TF-CBT + SSRI was held at the lower
level of 0.29 and 0.31 respectively, TF-CBT produced
12.45 QALYs at an additional cost of A$2,140, while TF-
CBT + SSRI generated slightly more QALYs (12.51) at a
marginally higher cost of A$2,314. Under these assump-
tions, non-directive counselling again dominated both TF-
CBT and TF-CBT + SSRI. The ICERs of TF-CBT and TF-
CBT + SSRI vs no treatment were A$2,489 and A$2,516
respectively. The ICER of TF-CBT + SSRI vs TF-CBT was
A$2,902. Conversely, when clinical effectiveness of both
TF-CBT and TF-CBT + SSRI was held at the upper level
of 0.57 and 0.55 respectively, non-directive counselling
was dominated by TF-CBT. The results of this two-way
sensitivity analysis were 13.27 QALYs at an additional cost
of A$1,221 for TF-CBT; 13.34 QALYs at an additional
cost of A$1,271 for TF-CBT + SSRI as compared to 12.61
QALYs at an additional cost of A$2,081 for non-directive
counselling.
Results of probabilistic sensitivity analysis including
95%CI around costs and QALY outcomes are shown in
Table 4.
While the mean values of costs and outcomes closely
approximate the point estimates obtained in the deter-
ministic base-case analysis reported in Table 3, the size
of the confidence intervals reflect the degree of uncer-
tainty around the parameter estimates included in the
model.
Discussion
The study adds to current knowledge about comparative
cost-effectiveness of different treatment options in the
population of sexually abused children and adolescents.
Governments in high-income countries increasingly rely
on economic evidence, preferably in the form of cost-
utility analysis [62,63], to inform decisions about fund-
ing of health services. Unlike NICE in the UK, Austra-
lian funding bodies do not use a fixed threshold in its
decision making. For example, past PBAC decisions sug-
gest the use of a background willingness to pay for
health gains that varies with the opportunity cost of the
proposed drug [64]. However, the listing of pharmaceu-
ticals on the PBS and receipt of considerable govern-
ment subsidy are more likely for interventions with
ICERs below A$50,000 per QALY gained [65]. In the
base-case and sensitivity analyses, ICERs for all three
active treatment alternatives were always less than A
$7,000 per QALY gained indicating that, when com-
pared to no treatment, each of these interventions
would likely be considered a good investment from the
perspective of the Australian mental health system.
Results are more equivocal for the comparison between
active treatments. The base-case results indicated that
non-directive counselling is dominated by other active
treatments: TF-CBT and TF-CBT + SSRI, and that effi-
ciency gain (more QALYs for a given investment) can be
achieved by allocating more resources towards these
therapies. However, this result was sensitive to variation
in the clinical effectiveness parameters with non-directive
counselling dominating TF-CBT and TF-CBT + SSRI
under certain assumptions. Moreover, while the best
available evidence suggests that TF-CBT + SSRI is more
effective (and more cost-effective) than TF-CBT alone,
there is a continuing debate about risks of suicidal beha-
viour/ideations associated with prescribing SSRIs to chil-
dren and adolescents [31,66]. The limited clinical
evidence used in the present study did not produce any
support for the elevated risk of suicidal behaviour/idea-
tions in the population of children and adolescents trea-
ted for PTSD secondary to sexual abuse with a
combination therapy of TF-CBT + SSRI [33]. Therefore
the outcomes of the modelled economic evaluation were
not adjusted for the adverse risk profile believed to be
associated with SSRI prescribing. However, it should be
noted that this also implies that results of the present
study are not generalisable beyond the population who
met the inclusion criteria used in the clinical trials that
informed the economic evaluation. In particular, if chil-
dren demonstrated suicidal behaviour or harm to others
at the pre-treatment assessment they would become
ineligible for TF-CBT with or without SSRI. In such
Table 4 Results of probabilistic sensitivity analysis of the long-term model (1000 trials)
Treatment options Mean cost per child in A$2010-2011
(95%CI)
Mean number of QALYs
(95%CI)
Mean incremental number of QALYs vs no
treatment
ICER
No treatment 0 11.57 - -
(10.24; 13.06)
Non-directive
counselling
2125 12.59 1.02 2083
(1927; 2335) (11.62; 13.57)
TF-CBT only 2097 12.85 1.28 1638
(1904; 2302) (11.98; 13.74)
TF-CBT + SSRI
(sertraline)
2271 12.92 1.35 1682
(2070; 2478) (12.01; 13.78)
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instances the PTSD Guideline suggests that healthcare
professionals should first concentrate on management of
these risks [20].
Although the evidence of the increased adolescent
mortality due to suicides believed to be associated with
SSRI prescribing is inconclusive [46] it is possible that
even with respect to children who did not experience
suicidal behaviour/ideations at the pre-treatment assess-
ment some clinicians and parents may exercise caution
when deciding on the best treatment option, and the
maximum health benefit associated with TF-CBT +
SSRI will not be achieved. Given uncertainty associated
with clinical effectiveness of the evaluated interventions,
it may not always be possible to achieve an optimal
decision in resource allocation where implementation of
that decision relies upon changes in prescribing practice
and patient preferences.
There is a scarcity of cost-utility studies in the paedia-
tric population and particularly in the area of child men-
tal health. In the absence of prospective epidemiological
studies in the population of sexually abused children,
the modelled evaluations rely on a number of assump-
tions that remain to be validated against future research,
although these are always legally and ethically challen-
ging. The economic evaluation reported here was under-
taken from a limited clinical perspective and does not
include the long-term social and economic implications
(employments, sexual health, educational achievements)
that would be required if a societal perspective was
undertaken. Currently there is no evidence that would
allow drawing an association between the degree of suc-
cess of different PTSD treatments and other socio-eco-
nomic factors that influence wellbeing of children and
adolescents.
In all modelled economic evaluations the validity of
results depends on the quality of data available and the
simplifying assumptions about progression of disease
over the modelled time horizon. For this model, clinical
effectiveness parameter estimates were obtained from
high quality RCTs, where reduction in PTSD symptoms
was the primary outcome. The outcomes of economic
evaluation therefore apply only to the comparative ana-
lysis of treatments used for trauma-related problems in
sexually abused children. All but one [33] of these RCTs
were used as an evidential basis in the Clinical Practice
Guideline for Management of PTSD in Adults and Chil-
dren [20]. The limited number of treatment alternatives
modelled reflects the lack of quality trials of other thera-
pies, e.g. child-parent psychotherapy, parent-child inter-
action therapy and structured group treatments [20,67].
Since there are no published utility estimates asso-
ciated with the health states included in the model,
health-state utility values and age-specific probabilities
of gradual recovery from PTSD over the modelled time
interval were obtained from the 2007 Australian
National Survey of Mental Health and Wellbeing [53].
Although the Mental Health Survey included a repre-
sentative sample of the Australian population, the num-
ber of young people aged 16-21 who reported a history
of childhood sexual abuse was limited to 82 respondents
and only a proportion of these respondents met DSM
diagnostic criteria for PTSD with or without depression.
Children younger than 16 years old were not included
in the survey necessitating assignment of utility esti-
mates obtained from the adolescent population to the
model cohort of children (10 years old at the baseline).
Nevertheless sensitivity analysis on utility estimates did
not produce outcomes that would invalidate the results
of the base-case analysis.
One of the strong assumptions of the model is that
the difference in effectiveness between the treatments
only relates to the first 12 months for which the post-
treatment and follow-up effectiveness outcomes are
available. There is no evidence to suggest that the likeli-
hood of recurrent depression or the propensity to seek
additional treatment in non-responders is influenced by
the type of initial treatment. In the absence of any sup-
porting evidence on the differential distribution of the
subsequent mental health conditions and the patterns of
health care resource use, it may be reasonable to suggest
that the more effective initial treatment will generate
additional savings by preventing a higher proportion of
the original cohort from seeking assistance for their
mental health problems in the future. From this point of
view, the “prognostic” model that extends results
observed at the 12 month follow-up over the next 30
years will generate a conservative ICER estimate.
It should also be noted that the existing clinical evi-
dence is limited to the first line of PTSD treatment in
sexually abused children. There is neither a clinical gui-
dance on the secondary treatment options for non-
responders nor reliable data on existing clinical prac-
tices. Therefore, the model is limited to the first line
PTSD treatment options, while subsequent health care
resource use relates only to the episodes of co-morbid
depression. While international cost-of-illness studies
suggest that PTSD is associated with a considerable
increase in health care resource use (around US$4,500
in 2005 prices adjusted for purchasing power parity
[68]), the direct medical cost data should be balanced
against the evidence of clinical effectiveness and ideally
reflect clinical pathways specific to PTSD secondary to
childhood sexual abuse.
In relation to the first line treatment, there is some evi-
dence that TF-CBT is under-represented in the current
mix of treatments. For example, a preliminary analysis of
the 2007 Australian Mental Health Survey data showed
that out of 400 respondents who had met DSM-IV
Gospodarevskaya and Segal Child and Adolescent Psychiatry and Mental Health 2012, 6:15
http://www.capmh.com/content/6/1/15
Page 12 of 15
criteria for PTSD in the last 12 month, only 18% reported
that they received CBT. Although respondents may be
lacking in their ability to accurately identify the type of
received treatment, the results are consistent with the
results of a survey of 852 psychologists in the USA,
where only 17% stated that they use exposure therapy for
PTSD [69]. Whereas the present study estimates the rela-
tive cost-effectiveness of alternative interventions, policy
decisions regarding active implementation of the Guide-
line recommendations would require estimation of the
net benefits associated with moving from current practice
patterns to the practice patterns recommended by the
PTSD Guideline. Based on the results of the economic
evaluation presented here, any treatment mix associated
with a higher proportion of children receiving TF-CBT
and TF-CBT + SSRI (as recommended by the PTSD
Guideline) is likely to be more cost-effective than the
current mix of treatments. This may raise a policy con-
cern regarding the availability of suitably trained psychol-
ogists and psychiatrists and the funding of their services.
Conclusion
Even after accounting for uncertainty in parameter esti-
mates, the results of the modelled economic evaluation
demonstrated that under Australian health services con-
ditions all active psychotherapy treatments for PTSD in
sexually abused children have a favourable ICER relative
to no treatment. The results also highlighted the loss of
quality of life in children who do not receive any psy-
chotherapy. Results are more equivocal for the compari-
son between active treatments. The base-case results
indicated that non-directive counselling is dominated by
other active treatments: TF-CBT and TF-CBT + SSRI,
and that efficiency gain (more QALYs for a given invest-
ment) can be achieved by allocating more resources
towards these therapies. On the basis of the best clinical
evidence, it is apparent that TF-CBT + SSRI is more
cost-effective than TF-CBT alone, however, considering
the uncertainty associated with prescribing SSRIs to
children and adolescents, clinicians and parents may
exercise some caution in choosing this treatment alter-
native, which may result in suboptimal allocation of the
scarce mental health services resource.
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